RegenxBio gets positive interim data for eye disease treatment

The prospect of RegenxBio’s product could change the game for the roughly 2 million people who suffer from wet age-related macular degeneration in the U.S., Europe and Japan.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.